Journal
IMMUNOLOGICAL REVIEWS
Volume 298, Issue 1, Pages 117-133Publisher
WILEY
DOI: 10.1111/imr.12920
Keywords
ACT; CAR T cells; CRISPR; engineering; solid tumor; V gamma 9V delta 2 T cells
Categories
Funding
- Association pour la Recherche contre le Cancer [PJA 20191209404]
- Ligue Contre le Cancer [AOGO2019]
- Association pour la Recherche sur le Cancer [PJA20191209404]
- Fondation pour la Recherche Medicale [FRM DEQ20170839118]
Ask authors/readers for more resources
Despite recent significant progress in cancer immunotherapies based on adoptive cell transfer(s)(ACT), the eradication of cancers still represents a major clinical challenge. In particular, the efficacy of current ACT-based therapies against solid tumors is dramatically reduced by physical barriers that prevent tumor infiltration of adoptively transferred effectors, and the tumor environment that suppress their anti-tumor functions. Novel immunotherapeutic strategies are thus needed to circumvent these issues. Human peripheral blood V gamma 9V delta 2 T cells, a non-alloreactive innate-like T lymphocyte subset, recently proved to be a promising anti-tumor effector subset for ACT-based immunotherapies. Furthermore, new cell engineering tools that leverage the potential of CRISPR/Cas technology open astounding opportunities to optimize their anti-tumor effector functions. In this review, we present the current ACT strategies based on engineered T cells and their limitations. We then discuss the potential of engineered V gamma 9V delta 2 T cell to overcome these limitations and improve ACT-based cancer immunotherapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available